Inogen (NASDAQ:INGN - Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect Inogen to post earnings of ($0.76) per share for the quarter. Inogen has set its Q1 2024 guidance at EPS.Persons interested in listening to the company's earnings conference call can do so using this link.
Inogen (NASDAQ:INGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The medical technology company reported ($1.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.49). Inogen had a negative return on equity of 38.98% and a negative net margin of 32.46%. The business had revenue of $75.90 million during the quarter, compared to analysts' expectations of $78.09 million. On average, analysts expect Inogen to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Inogen Stock Down 3.1 %
Shares of INGN stock traded down $0.22 during trading hours on Tuesday, hitting $6.80. 178,421 shares of the company's stock traded hands, compared to its average volume of 541,417. The stock's fifty day simple moving average is $7.29 and its two-hundred day simple moving average is $6.41. Inogen has a 12-month low of $4.13 and a 12-month high of $14.10. The stock has a market cap of $160.14 million, a price-to-earnings ratio of -1.54 and a beta of 1.06.
Analyst Upgrades and Downgrades
INGN has been the topic of a number of recent research reports. Needham & Company LLC reissued a "hold" rating on shares of Inogen in a research note on Tuesday, April 9th. William Blair upgraded shares of Inogen from a "market perform" rating to an "outperform" rating in a research note on Thursday, February 15th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $7.50.
View Our Latest Research Report on INGN
About Inogen
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
